Overview
NICE is unable to make a recommendation on idecabtagene vicleucel (Abecma) for treating relapsed or refractory multiple myeloma after 2 to 4 treatments in adults. This is because the company did not provide an evidence submission.
Last reviewed: 23 July 2025
Next review: We will review this decision if the company decides to make a submission.